Business Context and Reporting Period
This Form 6-K filing by Check-Cap Ltd. (noted as Mbody AI Ltd. in request metadata) covers the period of March 15, 2021. The registrant is a foreign private issuer based in Israel. The filing serves to incorporate a press release regarding a regulatory milestone into the company's existing registration statements.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a regulatory announcement and does not contain financial statements or performance data.
Material Changes
The material change reported is the receipt of Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) for the company's C-Scan(R) device. This approval enables the commencement of a pivotal clinical study.
Guidance, Outlook, and Risks
The filing incorporates "Forward Looking Statements" from the attached press release by reference, though the specific text of these statements is not included in the provided content. The primary outlook is the progression of the C-Scan(R) device through the pivotal study phase. No specific risks, contingencies, or unusual items are detailed in the filing text itself.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for details on the FDA IDE approval scope and timeline.
- Confirm the specific "Forward Looking Statements" incorporated by reference to understand management's projections.
- Review the company's most recent Form 20-F for actual financial performance data, as this 6-K contains none.
- Monitor the status of the pivotal study for C-Scan(R) as a key catalyst for future valuation.